ITM Isotope Technologies Munich SE (ITM) has secured €255 million from an investor syndicate led by Temasek of Singapore to advance its pipeline of radiopharmaceuticals for the treatment of cancer. The round, which was also supported by BlackRock Alternatives and the Qatar Investment Authority, will help advance the company’s lead product for neuroendocrine tumours and expand capacity for the production of targeted radionuclide therapies. These are a type of radiation therapy in which a radioactive chemical is linked to a cell-targeting molecule such as a peptide or small molecule.
